3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer

Authors

DOI:

https://doi.org/10.26641/2307-0404.2023.2.283254

Keywords:

non-muscle invasive bladder cancer, hyperthermic intravesical chemotherapy

Abstract

Cur   rently, the search for additional organ-sparing methods of intravesical therapy for non-muscular-invasive bladder cancer (NMIBC) is actively continuing, which could become an effective alternative to standard treatment using the Bacillus Calmette-Guérin (BCG) vaccine. The aim of this work was to analyze the safety profile and long-term results of treatment of patients with the high-risk non-muscular-invasive bladder cancer who received adjuvant intravesical chemotherapy using the Combat BRS HIVEC® device for local hyperthermia (HIVEC® therapy group; n=53) in comparison with patients who received adjuvant therapy after transurethral resection of bladder performed with the Bacillus Calmette-Guérin vaccine (BCG therapy group; n=54). As a result, the median follow-up was 30 months (range 7-36). According to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0, the most relevant side effects in HIVEC®/BCG therapy groups were adverse events grade 1-2: fever – 1%/8%; dysuria – 9%/13%; bladder spasms – 7%/12%; hematuria – 3%/4% and urinary tract infection – 3%/10%. Tumor recurrence was reported in 23 patients receiving intravesical BCG therapy and in 10 patients receiving intravesical hyperthermic chemotherapy (42.6% versus 18.9%, p=0.008). Tumor progression was recorded in 11 patients receiving intravesical BCG therapy and in 4 patients receiving intravesical hyperthermic chemotherapy (20.4% versus 7.5%, p=0.046). The study allows us to conclude that the method of hyperthermic intravesical chemotherapy has a better safety profile compared to intravesical Bacillus Calmette–Guérin vaccine therapy, while such indicators of oncological efficacy as 3-year recurrence-free survival and the incidence of progression were better in the HIVEC® therapy group.

References

Vozianov SA, Shamrayev SN, Stus VN, Krasnov VN, Vasylieva VD, Polion NYu, Shamrayeva DN. [Radical cystectomy: a comparative evaluation of perio-perative outcomes in patients with a complicated and uncomplicated postoperative period]. Zdorov'e muzhchiny. Russian. 2017;2:100-4. doi: https://doi.org/10.30841/2307-5090.2(61).2017.116643

Sharashova EE, Kholmatova KK, Gorbatova MA, Grjibovski AM. [The application of multiple logistic regression analysis in health sciences using SPSS software]. Nauka i zdravookhranenie. Russian. 2017;3:5-31. doi: https://doi.org/10.34689/SH.2020.19.4.001

Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) – 2019 Update. Eur Urol. 2019 Nov;76(5):639-57. doi: https://doi.org/10.1016/j.eururo.2019.08.016

Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genitourinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014 Jan;65(1):69-76. doi: https://doi.org/10.1016/j.eururo.2013.07.021

Kramer MW, Altieri V, Hurle R, Lusuardi L, Merseburger AS, Rassweiler J, et al. Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. Eur Urol Focus. 2017 Dec;3(6):567-76. doi: https://doi.org/10.1016/j.euf.2016.12.004

Larsen ES, Nordholm AC, Lillebaek T, Hol-den IK, Johansen IS. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019 Dec;124(6):910-6. doi: https://doi.org/10.1111/bju.14793

Parker WP, Smelser W, Lee EK, Habermann EB, Thapa P, Zaid HB, et al. Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients. Clin Genitourin Cancer. 2017 Aug 1:S1558-7673(17)30208-2. doi: https://doi.org/10.1016/j.clgc.2017.07.011

Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM, et al. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. J Clin Med. 2021 Oct 30;10(21):5105. doi: https://doi.org/10.3390/jcm10215105

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4;71(3):209-49. doi: https://doi.org/10.3322/caac.21660

Tan WS, Panchal A, Buckley L, Devall AJ, Lou-bière LS, Pope AM, et al. Radiofrequency-induced Thermochemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Er Uruol. 2019 Jan;75(1):63-71. doi: https://doi.org/10.1016/j.eururo.2018.09.005

Downloads

Published

2023-06-30

How to Cite

1.
Chystiakov R, Kostyev F, Bondar O, Lysenko V, Varbanets V. 3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer. Med. perspekt. [Internet]. 2023Jun.30 [cited 2024Nov.4];28(2):64-70. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/283254

Issue

Section

CLINICAL MEDICINE